WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 15-July-2016 (15-July-2016)
Next overall update Fall 2016
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 192
GDP / capita (US$): 1 Child (under 5 years) mortality rate: 212

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 543  538  533  529  523  481  408  363 
Births 10  10  10  10  10  11  11  11 
Surviving infants 10  10  10  10  10  10  11  10 
Pop. less than 5 years 48  48  49  49  49  53  53  45 
Pop. less than 15 years 145  146  147  147  148  161  139  144 
Female 15-49 years 140  139  138  137  136  121  103  87 

Number of reported cases

(Click for retrospective incidence data for Suriname)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  35  254 
Mumps
ChartChart
 
Pertussis
ChartChart
  13 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  40  11 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Suriname)
Vaccine year result method % card seen                                                
BCG         
DTP1 2005  96  MICS   81  90  91  91  80  90 
DTP3 2005  91  MICS   81  89  85  87  84  86  71  83  25 
DTP4          64  64 
IPV1          12 
HepB_BD          65  64  45  84 
HepB3 2005  MICS   81  89  85  86  84  86 
Hib3 2005  MICS   81  89  85  86  84  86 
JapEnc         
MCV1          94  85  93  73  85  71  65 
MCV2          28  18  18 
PCV1         
PCV3         
Pol3 2009  83  MICS   82  89  85  87  84  86  70  81  24 
Rota1         
RotaC         
Rubella1          94  85  93  73  85 
TT2plus 2009  27  MICS   82  76 
PAB         
VAD1         
YFV 2009  64  MICS   82  86  79  93  73  81 
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Suriname)
DTP1
ChartChart
  90  91  91  94  90  90  94  50 
DTP3
ChartChart
  89  85  86  84  86  71  83  25 
HepB3
ChartChart
  89  85  86  84  86 
HepB_BD
ChartChart
  65  64  45  51  46 
Hib3
ChartChart
  89  85  86  84  86 
IPV1
ChartChart
  12 
MCV1
ChartChart
  94  85  93  73  85  84  65 
MCV2
ChartChart
  28  18  18 
PAB
ChartChart
  93  93  93  93  93  92  92 
PCV3
ChartChart
 
Pol3
ChartChart
  89  85  86  84  86  70  81  24 
RCV1
ChartChart
  94  85  93  73  85  84 
RotaC
ChartChart
 
YFV
ChartChart
  86  79  76  73  10 

Number of districts in the country 10  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 50
From 80 to 89% 30
From 50 to 79% 20
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DT 5-7 years; Yes Children with contra-indication for Pertussis vaccine
DTwP 18 months; 4 years; Yes
DTwPHibHepB 2, 4, 6 months; Yes
HPV 9 years;+ 6 months; Yes
HepB_Adult 1st contact; +1, +5 months; Yes health care workers
HepB_Pediatric birth; Yes
IPV 2 months; Yes
Influenza_Adult No elderly, adults with chronic diseases, pregnant women and health care workers
MMR 1, 4 years; Yes
MenACWY 1st contact; Yes travelers
OPV 4, 6, 18 months; 4 years; Yes
Pneumo_conj No From 2017, risk groups
Rabies Yes
Td 1st contact; +1, +6 months; +1, +1 year; Yes pregnant women
Tdap No 3rd trimester of pregnancy (campaign)
YF 1 year; Yes

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  No  No  Yes 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number     10 

System performance

Total Nº districts in country number 10  10  10  10  10  10  10 
Nº districts with DTP3 coverage >=80% number  
% of districts with DTP3 coverage >=80% From 0 to 100% 80  80  80    90  90 
Nº districts with measles (MCV1) coverage >=95% number  
% of districts with MCV1 coverage >=95% From 0 to 100% 20  50    20  40 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes   
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 95  98    100  97  84  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  Yes  Yes  Yes  Yes  Yes   

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.